Sandra Horning, a director of CM Life Sciences III Inc., recently acquired 470,250 shares of the company. The buys took place at $0.00 per share (and therefore, likely the result of option or restricted share grants), on December 17, 2021. Horning now owns 470,250 shares of the company. Horning operates out of Cambridge, MA. Some additional info was provided as follows:
On December 17, 2021, upon consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of Legacy EQRx capital stock was excha
nged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock.
These options were issued under the Legacy EQRx 2019 Stock Option and Grant Plan (the "2019 Plan") and were assumed in the Business Combination pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock. The shares underlying this option vest and become exercisable in 16 equal quarterly installments commencing August 21, 2020, subject to the Reporting Person's continuous service as of each vesting date.
Upon consummation of the Business Combination, the Reporting Person received the right to acquire 107,364 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 75,155 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,209 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever CM Life Sciences III Inc. makes a similar move, sign up!
